Clinical Trial Update: FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update on FCN-159 for symptomatic, inoperable Neurofibromatosis type 1-related plexiform neurofibromas, sponsored by Shanghai Fosun Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• FCN-159

Snippet

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Conditions: Neurofibromatosis 1, Plexiform Neurofibroma | Phase 3 | Status: ACTIVE_NOT_RECRUITING